A new IQVIA Institute for Human Data Science report shows that significant rebates, discounts and limited access to medicines are keeping drug spending growth in check, though Pharmaceutical Research and Manufacturers of America (PhRMA) credits competition for slowing the compound annual growth rate (CAGR) for drug spending globally.
Clearly, both payer pressures on pricing and the need to price medicines competitively – especially in drug classes with multiple...





